Medibact GuidesShop at Medibact

Stacking Module

Follistatin 344 Stacking Module

Follistatin 344 is reported as a myostatin inhibitor, which places it outside every other mechanism in this catalog — it is the one compound whose stacking rationale does not overlap with GH signaling, repair signaling or metabolic pathways. It also has the weakest human evidence base of anything in the muscle-oriented group.

Follistatin 344 Guide at MedibactFollistatin 344 calculatorPeptide Stacking Guide

Educational use only — not medical advice. This page summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.

How to think about stacking Follistatin 344

  • Follistatin 344 is studied as a myostatin/activin-pathway inhibitor. That is genuinely distinct from GH-axis or IGF-1 signaling, which is why it is described as complementary to them rather than redundant.
  • Human data are very limited and largely absent for the injected research form. Reported protocols are community-derived.
  • It is reported on a microgram scale and in small vials; worked examples from larger vials do not transfer.
  • No controlled trial has studied it combined with anything.

Combinations in detail

Growth factor stack

Follistatin 344 + IGF-1 LR3 + MGF
Why it is proposed
Combines myostatin-pathway inhibition with IGF-1-family signaling on the premise that removing a brake and adding a signal are different things.
What is reported in practice
Reported as separate vials; the IGF-1-family components are often sequenced apart from each other.
Cautions specific to this combination
Three compounds with thin human data and no combination evidence. IGF-1 LR3 and MGF are themselves the same family, so this is arguably two mechanisms rather than three.

GH secretagogue pairing

Follistatin 344 + CJC-1295 + Ipamorelin
Why it is proposed
Myostatin-pathway inhibition alongside upstream GH-axis stimulation — clearly separate mechanisms.
What is reported in practice
Separate vials, separate schedules.
Cautions specific to this combination
No combination data. Follistatin's own evidence base for the injected form is the weakest element here.

Recovery and repair

Follistatin 344 + BPC-157 + TB-500
Why it is proposed
Adds the local repair pairing, mechanistically unrelated to myostatin signaling.
What is reported in practice
Separate vials on separate schedules.
Cautions specific to this combination
Scale differences; recompute each.

What to avoid, and why

  • Treating community dosing figures as established — the injected research form has essentially no human evidence base.
  • Assuming IGF-1 LR3 and MGF are two separate additions; both are IGF-1-family.
  • Copying unit figures from larger-vial compounds; Follistatin vials are small and the arithmetic differs.

Related reading

The Peptide Stacking GuideAll stacking pages

Every combination described here is reported practice or mechanism-level reasoning. No controlled trial has studied any of these combinations, and nothing on this page is a personal protocol, a dose recommendation, or medical advice.